S&P 500 Futures
(0.08%) 5 331.50 points

Dow Jones Futures
(0.01%) 40 140 points

Nasdaq Futures
(0.12%) 18 658 points

Oil
(-0.26%) $79.85

Gas
(0.38%) $2.64

Gold
(1.26%) $2 447.90

Silver
(2.83%) $32.15

Platinum
(0.31%) $1 093.40

USD/EUR
(0.03%) $0.920

USD/NOK
(-0.03%) $10.67

USD/GBP
(0.01%) $0.787

USD/RUB
(-0.32%) $90.68

Realtime updates for Takeda Pharmaceutical [TAK]

Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Last Updated17 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-0.68% $ 13.22

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally...

Stats
Today's Volume	1.01M
Average Volume	1.65M
Market Cap	41.48B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $0 ) 2024-06-26
Last Dividend	$0.270 ( 2022-09-29 )
Next Dividend	$0 ( N/A )
P/E	45.59
ATR14	$0.00600 (0.05%)

Volume Correlation

Long: -0.02 (neutral)

Short: 0.45 (neutral)

Signal:(63.041) Neutral

Takeda Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Takeda Pharmaceutical Correlation - Currency/Commodity

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

-0.02
( neutral )

Takeda Pharmaceutical Financials

Annual	2024
Revenue:	$4 263.76B
Gross Profit:	$2 184.97B (51.25 %)
EPS:	$92.09

FY	2024
Revenue:	$4 263.76B
Gross Profit:	$2 184.97B (51.25 %)
EPS:	$92.09

FY	2023
Revenue:	$4 027.48B
Gross Profit:	$2 783.41B (69.11 %)
EPS:	$204.29

FY	2022
Revenue:	$3 569.01B
Gross Profit:	$2 462.16B (68.99 %)
EPS:	$147.14

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Takeda Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 6.86 - average (95.53%) | Divividend Growth Potential Score: 5.00 - Stable (0.07%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.470	2008-09-25
Last Dividend	$0.270	2022-09-29
Next Dividend	$0	N/A
Payout Date	2022-12-12
Next Payout Date	N/A
# dividends	27	--
Total Paid Out	$11.88	--
Avg. Dividend % Per Year	1.27%	--
Score	3.06	--
Div. Sustainability Score	6.86
Div.Growth Potential Score	5.00
Div. Directional Score	5.93	--

Next Divdend (Est)
(2024-08-15)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2008	$0.470	3.54%
2009	$1.000	6.24%
2010	$0.533	4.02%
2011	$1.135	7.11%
2012	$1.110	7.35%
2013	$0.894	5.57%
2014	$0.822	4.87%
2015	$0.730	4.62%
2016	$0.829	4.27%
2017	$0.798	4.71%
2018	$0.802	3.34%
2019	$0.828	4.92%
2020	$0.850	4.27%
2021	$0.804	4.47%
2022	$0.270	1.96%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Royal	2023-10-30	Monthly	39	10.10%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0338	1.500	9.32	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00954	1.200	9.68	10.00	[0 - 0.3]
returnOnEquityTTM	0.0206	1.500	-0.882	-1.324	[0.1 - 1]
payoutRatioTTM	1.993	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.106	0.800	9.47	7.58	[1 - 3]
quickRatioTTM	0.500	0.800	-1.768	-1.414	[0.8 - 2.5]
cashRatioTTM	0.198	1.500	-0.0116	-0.0174	[0.2 - 2]
debtRatioTTM	0.321	-1.500	4.66	-6.99	[0 - 0.6]
interestCoverageTTM	1.022	1.000	-0.733	-0.733	[3 - 30]
operatingCashFlowPerShareTTM	452.81	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.32	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.666	-1.500	7.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.622	1.000	2.97	2.97	[0.2 - 0.8]
operatingProfitMarginTTM	0.0527	1.000	-0.946	-0.946	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.147	1.000	-0.297	-0.297	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.452	-1.162	[0.5 - 2]
Total Score				6.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.41	1.000	7.84	0	[1 - 100]
returnOnEquityTTM	0.0206	2.50	-0.567	-1.324	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.32	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0273	1.500	9.32	0	[0 - 0.4]
operatingCashFlowPerShareTTM	452.81	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.993	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.0209	1.500	-3.19	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.167	1.000	8.34	0	[0.1 - 0.5]
Total Score				5.00

Takeda Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.